Investor Presentation

NASDAQ: MIRA

April 2026

©2023 MIRA Pharmaceuticals, Inc. All Rights Reserved.

Investor Presentation | Nasdaq: MIRA

Management

Erez Aminov

Chief Executive Officer & Executive Chairman

Itzchak Angel, PhD

Chief Scientific Advisor

• Biotechnology executive with a track record of advancing drug candidates from preclinical

  development through IND submission and into clinical-stage development.

• Chairman and CEO of Mira Pharmaceuticals (Nasdaq: MIRA), where he has advanced the Company's lead program from preclinical development through IND submission and successful Phase 1 completion, and is progressing into Phase 2, while expanding the pipeline with

  additional candidates advancing toward IND.

• Proven ability to execute across clinical development, regulatory strategy, and capital markets, including securing financing and executing strategic asset acquisitions and licensing transactions to expand the pipeline and drive shareholder value.

• Also serves as Chairman and CEO of Telomir Pharmaceuticals (Nasdaq: TELO), where he is

  advancing an oncology program following IND submission.

• Over 40 years of experience in guiding medical, pharmaceutical, drug, and

  business development in both large and emerging companies.

• Expertise in small molecules, botanical drugs, Biotechnology products, delivery systems, medical devices, and drug-device combinations.

• Former Head of Pharmacology at Synthelabo (Sanofi-Aventis, Paris, France)

  where he participated in research and development of drugs such as Xatral

  (alfuzosin), Ambien (zolpidem) and Mizollen (mizolastine).

  Alan Weichselbaum, CPA, MBA

  Chief Financial Officer

  Alex Weisman, PhD

  Scientific Advisor

• Seasoned Financial Executive with 30+ years of experience in corporate finance, capital markets, and strategic advisory; currently CFO of both MIRA and Telomir Pharmaceuticals.

• Board and Advisory Leadership as Director of FinWise Bancorp (Nasdaq: FINW) and founder of The Wexus Group, advising growth-stage companies on capital structuring and exit strategies.

• Capital Markets Expertise gained through senior Wall Street roles, hedge fund management, and leadership in institutional transactions across public and private markets.

  • Occupied executive positions of VPR & D and Chief Scientist at numerous Israeli and international pharmaceutical companies.

  • Currently serve as an advisor and management team member for

    companies developing new products for the chemicals, pharmaceuticals, and

    food industries.

  • More than 30 years of experience in the development, characterization, scale-up, technology transfer, trouble shooting, production and registration of novel and generic drugs, and other pharmaceutical and chemical products.

    Investor Presentation | Nasdaq: MIRA

    1

    Confidential - Do Not Distribute

    
    
    

    Corporate Overview

    We are MIRA Pharmaceuticals- advancing a differentiated pipeline of oral therapies for neurologic, neuropsychiatric, and metabolic disorders. Built on safety and efficacy, our programs target high-value markets with significant unmet need and strong clinical demand.

    Our pipeline includes:

    Ketamir-2 - a next-generation oral ketamine analog with improved bioavailability, selectivity, and safety profile. Completed Phase 1 clinical study with favorable safety and tolerability; advancing toward Phase 2a in chemo-induced neuropathic pain.

    SKNY-1 - a THCV analog designed for obesity and smoking cessation. It modulates CB1, CB2, and MAO-B with receptor selectivity that minimizes psychiatric risk and supports metabolic balance.

    MIRA-55 - a THC analog designed to reduce anxiety and improve cognition in aging

    populations, showing activity across models of memory, inflammatory pain, and

    behavioral regulation.

    Investor Presentation | Nasdaq: MIRA 2

    
    
    Our Pipeline

    Indications

    Pre-Clinical

    Phase-I

    Phase-II

    Ketamir-2

    Chemo-Induced Peripheral

    Neuropathy (CIPN)

    Mira-55

    Inflammatory Pain

    SKNY-1

    Obesity

    Smoking Cessation

    
    
    

    Investor Presentation | Nasdaq: MIRA 3

    
    
    Ketamir-2: A Novel Oral Approach to Treating Neuropathic Pain

    An advanced ketamine analog with fewer side effects, better safety, and clinical-stage momentum.

    What is Ketamir-2?

    • A next-generation oral ketamine analog with improved bioavailability, selectivity, and safety profile, specifically engineered for neuropathic pain, chemotherapy-induced peripheral neuropathy (CIPN) and treatment-resistant depression.

      Neuropathic Pain: A Major Unmet Need:

    • Affects 7-10% of the global population, including patients with diabetic neuropathy, postherpetic neuralgia, CIPN and MS-related pain. Current treatments are often ineffective or come with significant side effects and addiction risks.

      Why It Matters to Pharma Leaders:

    • Existing therapies (anticonvulsants, SNRIs, opioids) offer limited efficacy and poor tolerability. DEA review confirmed

    • Ketamir-2 is not a controlled substance, making it a safer, rapid-acting oral alternative with clear regulatory and commercial advantages.

      Current Status:

    • Undergoing a Phase I clinical trial at Hadassah Medical Center in Israel, showing promising early tolerability and safety.

      Investor Presentation | Nasdaq: MIRA 4

      
      
      

      Key Therapeutic

      Area

      
      
      Neuropathic Pain: High Prevalence, Low Satisfaction, and Urgent Demand

      An underserved patient population where existing treatments fall short - and the risk of addiction

      runs high.

      
      
      

    • Widespread and Costly Neuropathic pain affects 7-10% of the population globally, often linked to diabetes, CIPN, MS, shingles, and nerve injury. It's one of the most common forms of chronic pain.

      Current Treatments Are Insufficient

    • First-line therapies like gabapentin, pregabalin, and SNRIs offer limited relief and come with CNS side effects, sedation, or tolerance concerns. Opioids are a last resort, burdened by addiction risk.

      No Oral, Rapid-Acting, Low-Abuse Option Exists Today

    • There's a significant gap in the market for a therapy that is oral, non-addictive, and provides fast-acting, targeted relief without psychomimetic or sedative effects.

      Opportunity

    • Entering this space positions any firm as a leader in next-generation non-opioid pain therapeutics, aligned with both public health priorities and long-term CNS portfolio expansion.

      Investor Presentation | Nasdaq: MIRA 5

      
      
      

      Key Therapeutic

      Area

      
      
      Treatment Resistance Depression (TRD) & Post-Traumatic Stress Disorder (PTSD): High Prevalence, Limited Options, and Urgent Demand

      An underserved patient population where existing treatments fall short - and safe, effective options

      remain scarce.

      
      
      

      Widespread and Costly:

      • TRD affects ~30% of major depression patients who fail ≥2 antidepressant therapies. PTSD affects 3.6% (past-year) and 6.8% (lifetime) of U.S. adults, with millions more worldwide.

        Current Treatments Are Insufficient:

      • TRD: Limited efficacy from SSRIs, SNRIs, and augmentation therapies; high relapse rates.

      • PTSD: Standard options (SSRIs, therapy) leave many patients with residual symptoms or intolerable side effects.

        No Oral, Rapid-Acting, Low-Abuse Option Exists Today:

      • Market gap for therapies that are fast-acting, well-tolerated, and non-addictive, addressing both mood and trauma-related symptoms.

        Opportunity:

      • TRD global market: $1.3-2.2B (2024-2025), growing 4-9% CAGR.

      • PTSD global market: $2.2-3.0B (2024), steady growth ~4% CAGR.

      • Expanding into TRD & PTSD positions Ketamir-2 as a potential first-in-class oral option across high-need psychiatric indications.

      Investor Presentation | Nasdaq: MIRA

      6 Confidential - Do Not Distribute

      
      
      Ketamir-2: CMC

      Simple and scalable process for drug substance and drug product production.

      Drug Substance Manufacturing Process

    • Simple, high yield drug substance synthesis

    • Source for Starting Material of high quality established and approved.

    • No impurities over 0.10% originated from Starting material in the Drug substance

    • High Drug substance quality attributes

    • Particle size distribution controlled by precipitation process

    • Scaled up to 1.7 kg /GMP batch

      Physical Properties

    • Complete characterization of crystalline form (FT-IR, Raman, SS-NMR, pXRD, SEM) performed.

    • Reproducibility of crystalline form for all manufactured lots confirmed.

      Stability Studies

    • Drug substance was found stable (no trends in quality parameters) for 9 months.

      Drug Product

    • Hard gelatine capsules of 50mg and 300 mg developed Dissolution criteria in accordance with USP requirements

    • Drug products were found stable (no trends in quality parameters) for 6 months.

      Investor Presentation | Nasdaq: MIRA 7

      
      
      
      
      

      Ketamir-2: Pharmacology Precision Targeting at the NMDA Receptor - Without the Collateral Effects

      A novel oral NMDA antagonist with selective PCP-site binding and

      none of ketamine's psychomimetic baggage.

    • Low-Affinity, Highly Selective NMDA Modulation Ketamir-2 acts as a low-affinity antagonist at the PCP-site of the NMDA receptor, with an

      IC₅₀of~100µM-avoiding the broader binding that drives ketamine's side

      effects.

      No Off-Target Binding to Problematic Sites

    • Unlike ketamine, Ketamir-2 does shows no binding to: AMPA, Kainate,

      Sigma, Glycine or Glutamate receptors

      → This greatly reduces psychosis-like effects, sedation, and misuse potential.

      Improved Safety Profile Confirmed in Nor-Ketamir Metabolite

    • Its active metabolite shows similarly selective NMDA antagonism (IC₅₀

      ~300 µM), reinforcing a consistent, predictable pharmacodynamic profile.

    • Differentiated CNS Action Without Hyperactivity or Euphoria In vivo data confirms no hyperlocomotion or euphoria, highlighting Ketamir-2's differentiated CNS profile in schizophrenia-relevant behavioral models.

      Binding and inhibition data for Ketamir-2 and Nor-Ketamir at the

      s

      tes.

NMDAPCP-site. No significant activity at other glutamatergic receptor

Investor Presentation | Nasdaq: MIRA 8

Unlike ketamine, Ketamir-2 does not induce hyperactivity - a key signal of reduced psychomimetic liability.

studies.

Investor Presentation | Nasdaq: MIRA 12

Following paclitaxel-induced neuropathy, Ketamir-2 demonstrated significant and progressive pain relief starting at 30mg/kg PO, with complete reversal to baseline levels at 100-300mg/kg-outperforming Gabapentin in this validated pain model.

Male Female

Investor Presentation | Nasdaq: MIRA 13

Demonstrates increased movement and velocity without hyperactivity - mirroring classical antidepressant responses in the Open Field Test

• Open Field Test is a validated model for screening antidepressant and anxiolytic activity.

• Ketamir-2treatmentledtoasignificant, dose-dependent increase in total distance moved (Panel A) and velocity (Panel B).

• This pattern aligns with classical antidepressant effects, suggesting improved mood and motivation.

• No significant effect was observed with ketamine (30 mg/kg PO)

  - underscoring Ketamir-2's differentiation.

• Trend toward increased time in the center of the field (Panel C) suggests potential anxiolytic activity.

• Behavioral effects observed with Ketamir-2 occurred without signs of psychomotor overstimulation.

  Figure: Open field parameters. (A) Distance moved(cm); (B) mean velocity (cm/seconds) and (C) cumulative time spent in center (seconds). Significance values were obtained through One-Way ANOVA.

  Investor Presentation | Nasdaq: MIRA 14

  
  
  Ketamir-2 Shows Anxiolytic-Like Effects in Elevated Plus Maze

  Demonstrates increased movement and time in center - consistent with reduced anxiety and enhanced exploratory behavior

  
  
  

• Elevated Plus Maze is a classical assay used to assess anxiolytic and antidepressant activity based on exploratory behavior.

• Mice treated with Ketamir-2 moved significantly farther (Panel A) and faster (Panel B) than vehicle controls - reflecting increased mobility.

• Time spent in closed arms decreased(Panel C), suggesting reduced

  anxiety and greater willingness to explore open spaces.

• Ketamir-2 effects were dose-dependent, with increased activity seen

  at 100-300 mg/kg.

• Ketamine (30 mg/kg PO) showed no significant improvement, further

  d. ifferentiating Ketamir-2's anxiolytic potential.

• These findings reinforce Ketamir-2's behavioral signature consistent

  with clinical antidepressant and anxiolytic profiles.

  Figure Elevated plus maze (EPM) parameters. (A) Distance moved(cm); (B) mean velocity (cm/seconds), (C) cumulative time spent in open arms (seconds. Significant values were obtained through One-Way ANOVA.

  Investor Presentation | Nasdaq: MIRA 15

  
  
  Ketamir-2: ADME Shows Superior Oral Bioavailability and Brain Penetration Potential

  Not a substrate of P-gp efflux transporter - enabling improved absorption and CNS exposure

  compared to ketamine

  
  
  

• Caco-2 assay results confirm Ketamir-2 is not a substrate for P-glycoprotein (P-gp), unlike ketamine.

• Ketamir-2 showed high intestinal absorption (AB: 80.6 × 10⁻⁶ cm/s) and low efflux (BA: -38.7), similar to the oral reference drug propranolol.

• In contrast, ketamine demonstrated higher efflux than absorption, a

  classic P-gp interaction profile.

• Net absorption(AB-BA)for Ketamir-2 was 41.9, compared to -15.1 for

  ketamine, supporting significantly better permeability.

• Predicted oral bioavailability of ~80%, exceeding that of ketamine's oral

  or intranasal routes.

• Supports potential for convenient, at-home, oral administration -

  improving treatment access and patient autonomy.

  Investor Presentation | Nasdaq: MIRA

  Figure: Data obtained from the CaCO-2 model of intestinal absorption. Propranolol, a commonly prescribed beta-blocker that is taken orally and used to treat hypertension, is included as a positive control. The intestinal absorption (AB), Intestinal efflux (BA) and net absorption (AB-BA) are shown.

  16

  
  
  Ketamir-2: ADME

  Rapidly absorbed and metabolized to active Nor-Ketamir

  Time

• Ketamir-2 pamoate in a specific 2-hydroxypropyl-beta-cyclodextrin(HP-β-CD formulation is rapidly absorbed

• It is metabolized to the Nor-Ketamir metabolite with has similar pcp-site activity and selectivity as Ketamir-2

• Nor-ketamir has a long elimination half life (4.3 hours, vs 0.25 hours for Ketamir-2) and high levels (Cmax of 250 and 22 ng/ml, respectively) , representing 100% bioavailability compared to IV levels.

• It is also present in the brain in several time points measured

  Investor Presentation | Nasdaq: MIRA 17

  
  
  Ketamir-2: ADME

  In Rats, females have higher levels of Ketamir-2 and Nor-Ketamir. Not seen in dogs.

  
  
  

• Female rats have a higher level of Ketamir-2 and Nor-Ketamir than males (Cmax of 127 and 1620 ng/ml Ketamir-2, and 1930 and 3790 ng/ml Nor-Ketamir, for males and females respectively)

• No kinetic sex differences were observed in dogs

• Figure depicts plasma levels following 100 mg/kg of Ketamir-2 oral administration

  Investor Presentation | Nasdaq: MIRA 18

  
  
  Ketamir-2: Toxicology

  Excellent safety and toxicology profile

• Ketamir-2 was found to be highly selective across a broad receptor, enzymes and channels panel

• Non-mutagenic, non-genotoxic in standard assays

• Not neurotoxic in NMDA specific neurotoxicity study

• NOAELs: 300 mg/kg/day in rats; 200 mg/kg/day in dogs

Investor Presentation | Nasdaq: MIRA 19

Investor Presentation | Nasdaq: MIRA